Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 16/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 12/20 | 1.00 |
| ▸ | HTR2B | P41595 | 8/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.55 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22087932 | 0.88 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL22087933 | 0.85 | ADORA3 (0.74) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL22088668 | 0.82 | ADORA3 (0.70) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL24220488 | 0.82 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL24220500 | 0.82 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL31668923 | 0.78 | ADORA3 (0.64) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL3740327 | 0.77 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMEM97 | |
| SCHEMBL24220643 | 0.77 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL24220484 | 0.76 | ADORA3 (0.72) | ADORA3ADORA1ADORA2AHTR2BOPRK1 | |
| SCHEMBL25612586 | 0.74 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ADORA1, ADORA2A, ADORA2B | ADORA3 4/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.